Labcorp stock gains on updated FY 2026 guidance and Q2 earnings beat

Published on 09/18/2026 at 13:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Labcorp stock trades near USD 323 after Q2 2026 earnings of USD 4.99 per share and USD 3.73 billion in revenue as of September 15, 2026. The company now guides FY 2026 EPS to USD 18.10–18.55 on revenue of USD 14.7–14.8 billion, broadly in line with consensus.

Aquarellbild eines gläsernen Bürogebäudes vor Skyline in Pastelltönen — Aquarellmalerei einer Stadtlandschaft mit gläsernem Firmensitz symbolisiert Labcorp, ISIN US50540R4092, im Gesundheitssektor, Illustration mit AI erstellt.

Labcorp stock (ISIN US50540R4092) is trading near a recent New York Stock Exchange closing level of USD 323.97 after the company beat expectations with its Q2 2026 results and issued updated FY 2026 guidance on earnings and revenue as of September 18, 2026. According to MarketBeat on September 18, 2026, Labcorp now expects FY 2026 earnings per share of USD 18.10 to USD 18.55 on revenue of USD 14.7 billion to USD 14.8 billion, broadly aligned with Wall Street estimates.

Guidance and Q2 2026 figures

The updated FY 2026 guidance is the key near-term driver for Labcorp stock, as it anchors investor expectations for the next fiscal year. According to MarketBeat on September 18, 2026, the EPS range of USD 18.10 to USD 18.55 compares with a consensus estimate of USD 18.34, while the revenue range of USD 14.7 billion to USD 14.8 billion is essentially in line with the Street’s USD 14.7 billion forecast.

For the most recent reported quarter, Q2 2026, Labcorp delivered earnings per share of USD 4.99 and revenue of USD 3.73 billion, both above market expectations. As summarized by MarketBeat, the company also maintained its quarterly dividend at USD 0.72 per share for the period, underscoring management’s confidence in cash flow and earnings stability.

Stock performance and valuation context

Labcorp stock recently closed at USD 323.97 on the New York Stock Exchange on September 15, 2026, representing a gain of 2.75 percent compared with the prior close of around USD 315.31. This move followed the Q2 2026 earnings beat and the raised guidance, as highlighted by an earlier corporate news overview that referenced the same closing level of USD 323.97 as a near-term benchmark for investors in mid-September 2026.

From a broader performance perspective, Labcorp has seen solid share-price appreciation in 2026. A recent analysis of the stock’s trajectory noted that, based on the September 15, 2026 closing price of USD 323.97, the shares had gained 28.7 percent year to date, with a 90-day return of 24.8 percent and a three-year total return of 63.9 percent, alongside a one-year return of 19.4 percent. These figures place Labcorp’s performance above many traditional healthcare peers over the same periods and suggest that investors have rewarded both the company’s execution and its strategic initiatives.

Analyst consensus and upside expectations

Analyst sentiment helps frame how the market interprets Labcorp’s guidance relative to its current valuation. According to MarketBeat on September 18, 2026, nine analysts currently rate Labcorp stock as a Buy and three rate it as a Hold, producing a consensus rating of Moderate Buy. The same overview reports an average analyst price target of USD 336.36, implying a modest upside of roughly 3.8 percent from the recent USD 323.97 closing price referenced for September 15, 2026.

In addition to the formal guidance, investors also consider qualitative commentary on growth drivers. One recent conference recap noted that Labcorp outlined a medium-term revenue growth target of 5 to 8 percent for 2026 and highlighted the role of artificial-intelligence-driven process improvements in its testing operations. While that discussion did not provide detailed quarter-by-quarter metrics, it reinforced the strategic narrative behind the numerical guidance, suggesting that management sees technology and efficiency gains as key levers for maintaining double-digit net margin levels over time.

Risks and sector backdrop

Despite the solid guidance and recent earnings beat, Labcorp stock still faces sector and company-specific risks that investors weigh against the upside case. In the broader healthcare and diagnostics landscape, reimbursement pressure from payers, regulatory changes around laboratory testing, and competitive dynamics from both large peers and specialized niche labs can influence pricing and volume growth. The reliance on AI and data analytics as a growth catalyst also introduces execution risk, as projects must translate into tangible productivity gains and margin expansion to justify the capital and operating expenditure involved.

From a valuation standpoint, the combination of an FY 2026 EPS midpoint around USD 18.33, derived from the guidance range of USD 18.10 to USD 18.55, and the recent share price in the low USD 320s suggests that Labcorp is trading at a forward price-earnings multiple in the high teens. For investors, the key question is whether the forecast 5 to 8 percent revenue growth and double-digit net margin trajectory for 2026 and beyond are sufficient to support that multiple in an environment where interest rates and sector rotations can quickly shift sentiment toward or away from defensive healthcare names.

Stock remains supported by recent gains

With Labcorp stock holding near USD 323.97 as of the September 15, 2026 New York close, the shares trade close to the average analyst price target of USD 336.36 and reflect the market’s recognition of the Q2 2026 earnings beat and the updated FY 2026 guidance. The combination of mid-single-digit to high-single-digit expected revenue growth, an EPS range that brackets consensus, and a maintained dividend of USD 0.72 per quarter provides a relatively balanced profile of growth and income for shareholders heading into the next set of results.